Ebola virus disease (Ebola) is a rare but severe illness with an average case fatality rate of approximately 50%. Two licensed vaccines against the Ebola virus, Orthoebolavirus zairense, are available: the single-dose rVSVΔG-ZEBOV-GP (ERVEBO) and the two-dose regimen of Ad26.ZEBOV and MVA-BN-Filo (Zabdeno/Mvabea). The Strategic Advisory Group of Experts on Immunization (SAGE) recommends ERVEBO for use during Ebola outbreaks. In 2021, a global stockpile of ERVEBO was established to ensure equitable, timely, and targeted access to vaccine doses for future outbreaks. From 2021 to 2023, a total of 145,690 doses of ERVEBO were shipped from the International Coordinating Group (ICG) stockpile. However, due to the few and rapidly contained outbreaks since 2021, most doses (139,120; 95%) were repurposed for preventive vaccination of high-risk groups, compared to outbreak response (6,570; 5%). Ensuring sufficient vaccine doses for emergency outbreak response remains the priority for the ICG stockpile, while investments, advocacy, and additional research are crucial for health system preparedness and resilience. The ICG stockpile reached 500,000 doses by 2022, with 518,890 doses as of December 2023. Of these, 208,390 (40%) were scheduled to expire in 2024. The majority of doses (139,120) were repurposed for preventive vaccination, while 6,570 were used for outbreak response. The Democratic Republic of the Congo (DRC) received the largest number of doses (111,000), followed by Uganda and Guinea-Bissau. Preventive vaccination of high-risk groups, such as healthcare workers, is crucial for reducing cases, hospitalizations, and deaths during outbreaks. The ICG stockpile has been used to support preventive vaccination campaigns, particularly in at-risk countries. However, the frequency of outbreaks, especially those linked to viral persistence, highlights the need for innovative strategies to protect survivors and prevent reintroduction. The availability of licensed Ebola vaccines is a significant advancement in prevention and global health security. In the absence of large-scale outbreaks, preventive vaccination of high-risk groups is important. Investments, advocacy, and research are essential for health system preparedness and resilience. The ICG stockpile remains focused on ensuring sufficient vaccine doses for emergency outbreak response.Ebola virus disease (Ebola) is a rare but severe illness with an average case fatality rate of approximately 50%. Two licensed vaccines against the Ebola virus, Orthoebolavirus zairense, are available: the single-dose rVSVΔG-ZEBOV-GP (ERVEBO) and the two-dose regimen of Ad26.ZEBOV and MVA-BN-Filo (Zabdeno/Mvabea). The Strategic Advisory Group of Experts on Immunization (SAGE) recommends ERVEBO for use during Ebola outbreaks. In 2021, a global stockpile of ERVEBO was established to ensure equitable, timely, and targeted access to vaccine doses for future outbreaks. From 2021 to 2023, a total of 145,690 doses of ERVEBO were shipped from the International Coordinating Group (ICG) stockpile. However, due to the few and rapidly contained outbreaks since 2021, most doses (139,120; 95%) were repurposed for preventive vaccination of high-risk groups, compared to outbreak response (6,570; 5%). Ensuring sufficient vaccine doses for emergency outbreak response remains the priority for the ICG stockpile, while investments, advocacy, and additional research are crucial for health system preparedness and resilience. The ICG stockpile reached 500,000 doses by 2022, with 518,890 doses as of December 2023. Of these, 208,390 (40%) were scheduled to expire in 2024. The majority of doses (139,120) were repurposed for preventive vaccination, while 6,570 were used for outbreak response. The Democratic Republic of the Congo (DRC) received the largest number of doses (111,000), followed by Uganda and Guinea-Bissau. Preventive vaccination of high-risk groups, such as healthcare workers, is crucial for reducing cases, hospitalizations, and deaths during outbreaks. The ICG stockpile has been used to support preventive vaccination campaigns, particularly in at-risk countries. However, the frequency of outbreaks, especially those linked to viral persistence, highlights the need for innovative strategies to protect survivors and prevent reintroduction. The availability of licensed Ebola vaccines is a significant advancement in prevention and global health security. In the absence of large-scale outbreaks, preventive vaccination of high-risk groups is important. Investments, advocacy, and research are essential for health system preparedness and resilience. The ICG stockpile remains focused on ensuring sufficient vaccine doses for emergency outbreak response.